Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2024Frontiers in OncologyOpen Access

IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJoaquín García-SolorioNational Institute of Genomic MedicineJNJuan Carlos Núñez-EnríquezMexican Social Security InstituteMJMarco Jiménez‐OlivaresNational Legal Medicine Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Garcia‐Solorio et al. (2024) studied this question.

synapsesocial.com/papers/68e708e0b6db643587682e16https://doi.org/10.3389/fonc.2024.1337954
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Persistently high incidence rates of childhood acute leukemias from 2010 to 2017 in Mexico City: A population study from the MIGICCL2022 · 24 citations
  2. 2Ikaros, Aiolos and Helios: Transcription regulators and lymphoid malignancies2003 · 143 citations
  3. 3Homozygous Deletion of the p16/MTS1 Gene in Pediatric Acute Lymphoblastic Leukemia Is Associated With Unfavorable Clinical Outcome1997 · 104 citations
  4. 4The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms2022 · 4,054 citations
  5. 5Frequency and prognostic impact of PAX5 p. P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol2020 · 27 citations